Literature DB >> 19297133

Pathways to functional outcomes in schizophrenia: the role of premorbid functioning, negative symptoms and intelligence.

N Brill1, S Z Levine, A Reichenberg, G Lubin, M Weiser, J Rabinowitz.   

Abstract

BACKGROUND: Social and intellectual premorbid functioning are generally estimated retrospectively, and related to clinical or hospitalization outcomes in schizophrenia. Yet the relationship between premorbid functioning assessed prior to psychiatric hospitalization and postmorbid functional outcomes has not been examined.
OBJECTIVES: To test competing models of the relationship between (a) functional outcomes with (b) premorbid functioning assessed on nationally administered tests prior to psychiatric hospitalization, postmorbid intellectual functioning and symptomatology using a historical prospective design.
METHODS: Ninety one inpatient and outpatient males with schizophrenia or schizoaffective disorder, aged 19 to 35, were examined using the Positive and Negative Syndrome Scale, the WAIS-III and Strauss and Carpenter social and occupational functional outcome scale. Premorbid intelligence and social functioning data were obtained from national standardized tests administered during high school prior to first hospitalization for schizophrenia.
RESULTS: Path modeling showed that premorbid intelligence and behavioral functioning directly predicted postmorbid IQ and negative symptoms, and indirectly predicted postmorbid social and occupational functioning via negative symptoms. Item level analysis indicated that better social and occupational outcomes occurred in a group with few negative symptoms.
CONCLUSIONS: Premorbid functioning, postmorbid IQ and negative symptoms are related, yet the relationship between premorbid functioning and postmorbid functional outcomes appears to be mediated by postmorbid negative symptoms.

Entities:  

Mesh:

Year:  2009        PMID: 19297133     DOI: 10.1016/j.schres.2009.02.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients.

Authors:  Paola Salvatore; Ross J Baldessarini; Mauricio Tohen; Hari-Mandir K Khalsa; Jesus Perez Sanchez-Toledo; Carlos A Zarate; Eduard Vieta; Carlo Maggini
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

2.  Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI.

Authors:  Amy Pinkham; James Loughead; Kosha Ruparel; Wen-Chau Wu; Eve Overton; Raquel Gur; Ruben Gur
Journal:  Psychiatry Res       Date:  2011-08-09       Impact factor: 3.222

3.  Pathways between early visual processing and functional outcome in schizophrenia.

Authors:  Y Rassovsky; W P Horan; J Lee; M J Sergi; M F Green
Journal:  Psychol Med       Date:  2010-05-19       Impact factor: 7.723

4.  Effects of duration of untreated psychosis on long-term outcome of people hospitalized with first episode schizophrenia.

Authors:  Amresh Shrivastava; Nilesh Shah; Megan Johnston; Larry Stitt; Meghana Thakar; Gurusamy Chinnasamy
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

5.  The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study.

Authors:  Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Teresa Sanchez-Gutierrez; Giada Tripoli; Fabio Seminerio; Crocettarachele Sartorio; Giovanna Marrazzo; Lucia Sideli; Celso Arango; Manuel Arrojo; Miguel Bernardo; Julio Bobes; Cristina Marta Del-Ben; Charlotte Gayer-Anderson; Hannah E Jongsma; James B Kirkbride; Antonio Lasalvia; Sarah Tosato; Pierre-Michel Llorca; Paulo Rossi Menezes; Bart P Rutten; Jose Luis Santos; Julio Sanjuán; Jean-Paul Selten; Andrei Szöke; Ilaria Tarricone; Roberto Muratori; Andrea Tortelli; Eva Velthorst; Victoria Rodriguez; Andrea Quattrone; Peter B Jones; Jim Van Os; Evangelos Vassos; Craig Morgan; Lieuwe de Haan; Ulrich Reininghaus; Alastair G Cardno; Marta Di Forti; Robin M Murray; Diego Quattrone
Journal:  Schizophr Res       Date:  2021-08-14       Impact factor: 4.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.